CoChat

Histone Lysine Methyltransferase Wolf-Hirschhorn Syndrome Candidate 1 Is Involved in Human Carcinogenesis through Regulation of the Wnt Pathway

Open access
Toyokawa, Gouji, Cho, Hyun-Soo, Masuda, Ken, Yamane, Yuka, Yoshimatsu, Masanori, Hayami, Shinya, Takawa, Masashi, Iwai, Yukiko, Daigo, Yataro, Tsuchiya, Eiju, Tsunoda, Tatsuhiko, Field, Helen I., Kelly, John D., Neal, David E., Maehara, Yoshihiko, Ponder, Bruce A.J., Nakamura, Yusuke, Hamamoto, Ryuji · 2011 · Neoplasia
Cited by 98

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

A number of histone methyltransferases have been identified and biochemically characterized, but the pathologic roles of their dysfunction in human diseases like cancer are not well understood. Here, we demonstrate that Wolf-Hirschhorn syndrome candidate 1 (WHSC1) plays important roles in human carcinogenesis. Transcriptional levels of this gene are significantly elevated in various types of cancer including bladder and lung cancers. Immunohistochemical analysis using a number of clinical tissues confirmed significant up-regulation of WHSC1 expression in bladder and lung cancer cells at the protein level. Treatment of cancer cell lines with small interfering RNA targeting WHSC1 significantly knocked down its expression and resulted in the suppression of proliferation. Cell cycle analysis by flow cytometry indicated that knockdown of WHSC1 decreased the cell population of cancer cells at the S phase while increasing that at the G(2)/M phase. WHSC1 interacts with some proteins related to the WNT pathway including β-catenin and transcriptionally regulates CCND1, the target gene of the β-catenin/Tcf-4 complex, through histone H3 at lysine 36 trimethylation. This is a novel mechanism for WNT pathway dysregulation in human carcinogenesis, mediated by the epigenetic regulation of histone H3. Because expression levels of WHSC1 are significantly low in most normal tissue types, it should be feasible to develop specific and selective inhibitors targeting the enzyme as antitumor agents that have a minimal risk of adverse reaction.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1593/neo.11048

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 98

Metadata

Authors
Toyokawa, G., Cho, H.-S., Masuda, K., Yamane, Y., Yoshimatsu, M., Hayami, S., Takawa, M., Iwai, Y., Daigo, Y., Tsuchiya, E., Tsunoda, T., Field, H. I., Kelly, J. D., Neal, D. E., Maehara, Y., Ponder, B. A. J., Nakamura, Y., & Hamamoto, R.
Venue
Neoplasia
Publisher
Elsevier BV
Published
2011-10
Volume
13
Issue
10
Pages
887-IN11
ISSN
1476-5586 (ISSN-L)
OpenAlex
W2102769765
Cited by
98
References
5
FWCI
2.59
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Histone Lysine Methyltransferase Wolf-Hirschhorn Syndrome Candidate 1 Is Involved in Human Carcinogenesis through Regulation of the Wnt Pathway. https://app.cochat.ai/papers/10.1593/neo.11048
The paper
Toyokawa, G., Cho, H.-S., Masuda, K., Yamane, Y., Yoshimatsu, M., Hayami, S., Takawa, M., Iwai, Y., Daigo, Y., Tsuchiya, E., Tsunoda, T., Field, H. I., Kelly, J. D., Neal, D. E., Maehara, Y., Ponder, B. A. J., Nakamura, Y., & Hamamoto, R. (2011). Histone Lysine Methyltransferase Wolf-Hirschhorn Syndrome Candidate 1 Is Involved in Human Carcinogenesis through Regulation of the Wnt Pathway. Neoplasia. https://doi.org/10.1593/neo.11048

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.